Arovella Therapeutics Ltd (ASX: ALA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Arovella Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$174.80 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.06 billion
Earnings per share
-0.009
Dividend per share
N/A
Year To Date Return
47.83%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Arovella Therapeutics Ltd (ASX: ALA)
Latest News
Share Market News
Suda Pharmaceuticals share price soars 200% on TGA approval
ALA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Arovella Therapeutics Ltd
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
ALA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.17 | $-0.01 | -5.56% | 1,636,299 | $0.18 | $0.18 | $0.17 |
| 19 Dec 2024 | $0.18 | $0.01 | 5.88% | 682,011 | $0.17 | $0.18 | $0.17 |
| 18 Dec 2024 | $0.17 | $0.00 | 0.00% | 584,020 | $0.17 | $0.18 | $0.17 |
| 17 Dec 2024 | $0.17 | $-0.01 | -5.56% | 1,031,736 | $0.18 | $0.18 | $0.17 |
| 16 Dec 2024 | $0.18 | $0.02 | 12.12% | 1,617,058 | $0.17 | $0.18 | $0.16 |
| 13 Dec 2024 | $0.17 | $-0.02 | -11.11% | 2,360,660 | $0.19 | $0.19 | $0.17 |
| 12 Dec 2024 | $0.18 | $0.01 | 5.71% | 521,682 | $0.19 | $0.19 | $0.18 |
| 11 Dec 2024 | $0.18 | $-0.01 | -5.56% | 2,305,992 | $0.19 | $0.20 | $0.18 |
| 10 Dec 2024 | $0.18 | $-0.01 | -5.26% | 722,859 | $0.19 | $0.19 | $0.18 |
| 09 Dec 2024 | $0.19 | $0.01 | 5.41% | 176,030 | $0.19 | $0.19 | $0.19 |
| 06 Dec 2024 | $0.19 | $-0.01 | -5.26% | 952,680 | $0.19 | $0.20 | $0.19 |
| 05 Dec 2024 | $0.19 | $0.02 | 11.43% | 628,727 | $0.18 | $0.19 | $0.18 |
| 04 Dec 2024 | $0.18 | $-0.01 | -5.41% | 582,164 | $0.18 | $0.19 | $0.18 |
| 03 Dec 2024 | $0.19 | $0.01 | 5.56% | 1,716,661 | $0.18 | $0.19 | $0.18 |
| 02 Dec 2024 | $0.18 | $-0.01 | -5.26% | 902,552 | $0.19 | $0.19 | $0.18 |
| 29 Nov 2024 | $0.19 | $0.00 | 0.00% | 2,512,976 | $0.19 | $0.20 | $0.19 |
| 28 Nov 2024 | $0.19 | $0.01 | 5.56% | 1,298,621 | $0.18 | $0.19 | $0.18 |
| 27 Nov 2024 | $0.18 | $-0.01 | -5.41% | 343,812 | $0.19 | $0.19 | $0.18 |
| 26 Nov 2024 | $0.19 | $-0.01 | -5.26% | 454,385 | $0.19 | $0.19 | $0.18 |
| 25 Nov 2024 | $0.19 | $0.00 | 0.00% | 755,040 | $0.19 | $0.19 | $0.18 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Nov 2024 | Gary Phillips | Issued | 354,000 | $65,490 |
Director remuneration.
|
| 26 Nov 2024 | Thomas (Tom) Duthy | Issued | 620,000 | $114,700 |
Director remuneration.
|
| 26 Nov 2024 | Michael Baker | Issued | 1,658,483 | $306,819 |
Director remuneration.
|
| 26 Nov 2024 | Debora Barton | Issued | 354,000 | $65,490 |
Director remuneration. As per announcement on 29-11-2024
|
| 26 Nov 2024 | Elizabeth Stoner | Issued | 354,000 | $65,490 |
Director remuneration.
|
| 28 Mar 2024 | Gary Phillips | Buy | 66,666 | $10,000 |
On-market trade.
|
| 28 Mar 2024 | Thomas (Tom) Duthy | Buy | 103,000 | $14,935 |
On-market trade.
|
| 27 Mar 2024 | Michael Baker | Buy | 220,000 | $31,289 |
On-market trade.
|
| 29 Dec 2023 | Michael Baker | Exercise | 2,800,000 | $322,000 |
Exercise of options.
|
| 29 Dec 2023 | Michael Baker | Buy | 587,824 | $67,599 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gary Phillips | Non-Executive Director | Jul 2022 |
Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
|
| Dr Thomas (Tom) Duthy | Non-Executive ChairmanNon-Executive Director | Mar 2023 |
Dr Duthy has over 20 years of direct financial markets experience and is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors.
|
| Mr David Simmonds | Non-Executive Director | Mar 2019 |
Mr Simmonds was a senior audit partner with Ernst & Young. David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David was a member of the Board and chaired the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.
|
| Dr Michael Baker | Chief Executive OfficerManaging Director | Jan 2020 |
Dr Baker has over 15 years of experience in scientific research, drug development and venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities, and research institutes.
|
| Dr Debora Barton | Non-Executive Director | Aug 2021 |
Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world.
|
| Dr Elizabeth Stoner | Non-Executive Director | Nov 2021 |
Dr Stoner has over 30 years of experience in the life-science sector. She is currently an executive partner at MPM Capital, a leading US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including Antiva, and Rhythm Pharmaceuticals.
|
| Mr Tim Luscombe | Chief Financial OfficerCompany Secretary | Dec 2023 |
-
|
| Tim Luscombe | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company (Australia) Limited Mbf A/C | 59,019,000 | 5.62% |
| MB Investment Capital Pty Ltd | 27,749,415 | 2.64% |
| UBS Nominees Pty Ltd | 25,620,196 | 2.44% |
| Mr James Evan Hughes-Morris | 21,917,196 | 2.09% |
| Blackburne Capital Pty Ltd Blackburne Capital A/C | 20,695,706 | 1.97% |
| Mann Beef Pty Ltd | 20,000,000 | 1.90% |
| Mann Beef Pty Ltd i | 19,555,555 | 1.86% |
| DP Investment Capital Pty Ltd | 18,000,000 | 1.71% |
| Dylide Pty Ltd | 17,166,666 | 1.63% |
| TK Cooper Holdings Pty Ltd | 15,186,620 | 1.45% |
| M & M Stock One Pty Ltd The M & M Stock One A/C | 13,596,581 | 1.29% |
| Mr Neil Donald Delroy The Ndd Investment A/C | 13,067,222 | 1.24% |
| Ajava Holdings Pty Ltd | 12,543,194 | 1.19% |
| Murray James Way Pty Ltd | 12,022,400 | 1.14% |
| Mann Beef Pty Ltd Lochwall Super Fund A/C | 11,350,102 | 1.08% |
| Mrs Naomi Hughes Morris | 11,309,868 | 1.08% |
| Moovnup Pty Ltd Moovnup A/C | 11,067,962 | 1.05% |
| Widerange Corporation Pty Ltd | 10,390,789 | 0.99% |
| Mr Richard John Mann | 10,000,000 | 0.95% |
| Mr Brendan John Martin & Mrs Sharon Ann Martin Jaknic Super A/C | 9,564,970 | 0.91% |
